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Abstract
Antenatal corticosteroids (ACS) are standard of care for women at risk of preterm delivery,
although choice of drug, dose or route have not been systematically evaluated. Further,
ACS are infrequently used in low resource environments where most of the mortality from
prematurity occurs. We report proof of principle experiments to test betamethasone-phos-
phate (Beta-P) or dexamethasone-phosphate (Dex-P) given orally in comparison to the clini-
cal treatment with the intramuscular combination drug beta-phosphate plus beta-acetate in
a Rhesus Macaque model. First, we performed pharmacokinetic studies in non-pregnant
monkeys to compare blood levels of the steroids using oral dosing with Beta-P, Dex-P and
an effective maternal intramuscular dose of the beta-acetate component of the clinical treat-
ment. We then evaluated maternal and fetal blood steroid levels with limited fetal sampling
under ultrasound guidance in pregnant macaques. We found that oral Beta is more slowly
cleared from plasma than oral Dex. The blood levels of both drugs were lower in maternal
plasma of pregnant than in non-pregnant macaques. Using the pharmacokinetic data, we
treated groups of 6–8 pregnant monkeys with oral Beta-P, oral Dex-P, or the maternal intra-
muscular clinical treatment and saline controls and measured pressure-volume curves to
assess corticosteroid effects on lung maturation at 5d. Oral Beta-P improved the pressure-
volume curves similarly to the clinical treatment. Oral Dex-P gave more variable and nonsig-
nificant responses. We then compared gene expression in the fetal lung, liver and hippo-
campus between oral Beta-P and the clinical treatment by RNA-sequencing. The
transcriptomes were largely similar with small gene expression differences in the lung and
liver, and no differences in the hippocampus between the groups. As proof of principle, ACS
therapy can be effective using inexpensive and widely available oral drugs. Clinical dosing
strategies must carefully consider the pharmacokinetics of oral Beta-P or Dex-P to minimize
fetal exposure while achieving the desired treatment responses.
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Introduction
Although Standard of Care for women at risk of preterm delivery in high income countries [1,
2], antenatal corticosteroids (ACS) are inconsistently used in low resource environments
despite endorsement of the World Health Organization [3]. ACS were considered to be the
number one intervention to decrease mortality from prematurity in low resource environ-
ments in a 2015 World Health Organization report [4]. A recent analysis emphasizes that ACS
alone may have only a modest impact on mortality without other improvements in diagnostic,
obstetric and newborn care [5]. And there are potential risks of ACS in low resource environ-
ments such as hypoglycemia that may be unrecognized an untreated [6]. The largest trial in
low resource environments demonstrated no benefit for low birth weight infants and increased
perinatal mortality for all treated pregnancies [7]. A general concern about ACS is that the
choice of drug and treatment schedule has not been optimized despite indications that current
dosing strategies may expose the fetus to higher doses of these potent corticosteroids than is
necessary for the desired maturational effects [8, 9]. The accepted ACS treatments are maternal
Intramuscular with either a 1 to 1 mixture of betamethasone phosphate and betamethasone
acetate (Beta-P + Beta-Ac) given as two 12 mg doses 24 hour apart or four doses maternal
intramuscular of 6 mg dexamethasone phosphate (Dex-P) given at 12 hour intervals [4, 10].
We demonstrated that a single dose of Beta-Ac alone that exposed the fetus to low Beta levels
was equivalent to the clinical treatment for lung maturational responses in fetal sheep and
monkeys [11, 12]. Maternal infusions of Beta-P to achieve low constant fetal exposures to Beta
also cause lung maturation in fetal sheep [13]. However, Beta-Ac is not available as a single
component drug and maternal infusions are impractical, particularly in low resource environ-
ments. As corticosteroid toxicity is proportionate to dose even for short-term exposures [14],
our long-term goal is to develop a lower dose and presumably safer treatment option for ACS.
We recently reported that oral corticosteroids were effective for ACS in a sheep model [15].
We have extended these observations to the non-human primate by evaluating the pharmaco-
kinetics and lung maturational effects of oral Dex-P and Beta-P as inexpensive and readily
available alternatives for ACS. The study also includes mRNA sequencing of fetal lung, hippo-
campus and liver to evaluate both lung and systemic effects of oral dosing of ACS. These pri-
mate studies are essential proof of concept observations that can help justify randomized
controlled trials of new ACS treatment options for worldwide use.
Methods
Overview of animal studies
Rhesus macaques were studied in the California National Primate Research Center at the Uni-
versity of California Davis with approved procedures and protocols (Protocol #20333). For
ultrasonography animals received intramuscular injections of Ketamine or Telazol at appro-
priate dosing. For hysterotomy, animals receive analgesia followed by inhalation anesthesia
using isoflurane performed by a CNPRC veterinarian and anesthesia technician. Procedures
were clustered to minimize pain, distress and reduce animal manipulations. After delivery
Rhesus macaques fetuses were euthanized with an overdose of pentobarbital (60mg/kg) prior
to necropsy. Rhesus mothers that were not euthanized after delivery received 0.15mg/kg of
oxymorphone 3 times a day for 3 days for postoperative analgesia. The CNPRC staff carefully
observed the animals post anesthesia until awake and active. Animals were monitored daily for
food intake, fecal output, hydration and activity. Discomfort was scored daily for 3 days and
sutures assessed daily for 7 days post-operative. Animals were monitored for infection, suture
reaction or dehiscence. Animals were treated as considered appropriate by the CNPRC
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veterinary staff. In case the attending veterinarian at the CNPRC deemed euthanasia of the
mother necessary for clinical reasons, it was performed with an overdose of IV pentobarbital
(60mg/kg).
Measurements of Beta and Dex were made in non-pregnant reproductive age animals and
selectively in gestationally dated pregnant animals. Other gestationally dated animals were
treated with the maternal, oral or intramuscular corticosteroids or with a saline placebo and
the fetuses were delivered in cull by cesarean section 5 days after the initiation of treatments.
The descriptions of the treatment groups, gestational ages, birth weights and fetal sex of the
animals are in Table 1. The Beta-P + Beta-Ac (Celestone1, Merck, Sharp and Dohme, Kenil-
worth, NJ) and Beta-Ac (a gift of this component of the clinical product from Merck, Sharp
and Dohme) were given by intramuscular injections. The oral Beta-P (Focus Pharmaceuticals
Ltd., London, UK) and Dex-P (Fresenius Kabi USA LLC, Lake Zurich, IL) were given in
bananas to monkeys habituated to receiving small treats. The drugs were mixed into Kool Aid
and rice cereal that were embedded in the middle of 1/4 of a banana.
The groups of non-pregnant animals used for pharmacokinetic studies had been accultur-
ated to blood draws without restraint or anesthesia. Limited paired maternal and fetal blood
samples from animals sedated with Ketamine were collected using ultrasound to guide the col-
lection of a small volume of blood from umbilical cord and venous blood from the dam.
Fetuses at delivery had blood drawn from the cord vessels just prior to euthanasia with pento-
barbital given IV. The fetal chest was opened, the trachea cannulated, and a pressure-volume
curve was measured using a syringe and manometer to inflate the lung to 40 cm H2O pressure
with air and then to deflate the lung with recording of pressure and volume [16]. The lungs
were weighed, and the left lung was used for four pooled alveolar washes with saline. The right
Table 1. Animal groups and treatments.
Treatment Group (N) Purpose Dosing Treatment to delivery interval
(days)
GA at
delivery
(days)
Fetal
Weight
(g)
Fetal Sex (M/
F)
Controls 6 Negative Control Saline 5 132 ± 2 320 ± 37 4/2
Beta-Ac + Beta-P
Maternal IM
6 Clinical dosing–Positive
control
0.25 mg/kg x 2–0 and
24 hr.
5 133 ± 1 330 ± 46 4/2
Beta-Ac–Maternal IM 3 Adult non-pregnant blood
levels
0.125 mg/kg x 1 — — — —
4 Maternal and fetal blood
levels
0.125 mg/kg x 2–0 and
24 hr.
5 130 ± 3 291 ± 19 2/2
Dex-P—Oral 3 Low dose
Adult non-pregnant blood
levels
0.04 mg/kg x1 — — — —
3 High dose
Adult non-pregnant blood
levels
0.15 mg/kg x 1 — — — —
4 Maternal and fetal blood
levels
0.15 mg/kg x2–0 and 24
hr.
5 130 ± 3 320 ± 26 1/3
5 Efficacy—Low dose 0.04 mg/kg x4–6 hr
interval
5 130 ± 2 387 ± 38 4/2
8 Efficacy–blood levels 0.15 mg/kg x3–12 hr
interval
5 131 ± 1 131 ± 48 6/2
Beta-P—Oral 3 Adult non-pregnant blood
levels
0.15 mg/kg x 1 — — — —
7 Efficacy 0.15 mg/kg x 3–12 hr
interval
5 130 ± 2 300 ± 34 3/4
https://doi.org/10.1371/journal.pone.0222817.t001
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lung lower lobes were sampled for cryopreservation and the right upper lobe was inflation
fixed at 30 cm H2O pressure with 10% formalin.
Measurements on maternal and fetal blood and alveolar wash
We measured complete blood counts, CD4, CD8 and B-cells by FACS, and plasma glucose on
selected samples. Cortisol was measured using an ELISA kit (EA65, Oxford Biomedical
Research, Rochester Hills, MI). Plasma was extracted with deuterated Beta or Dex added to
estimate recovery efficacy and analyzed by mass spectrometry as before [17]. Saturated phos-
phatidylcholine (SAT-PC) in alveolar wash was measured by phosphorous assay following
lipid extraction and treatment of the lipid extracts with osmium tetroxide [18]. Surfactant pro-
tein SP-D was measured in alveolar wash by ELISA using a SPD detection kit (cat#
RD194059101, Biovendor, Ashville NC).
mRNA measurements
We extracted total RNA from frozen lungs, hippocampus and liver using RNeasy Universal
Mini kits (Qiagen, Valencia, CA). Specific sequences for Rhesus were used to measure mRNA
in lung for the surfactant proteins SP-A, B, C, D and other maturational mRNA marker genes
(ABCA3, LAMP3, LPCAT1 and SCNN1G) by PCR.
Quality and integrity of total RNA from fetal lung, liver and hippocampus were verified for
RNA sequencing using the Agilent 2100 Bioanalyzer (Agilent, Agilent Technologies, Santa
Clara, CA). The Cincinnati Children’s Hospital Medical Center DNA Sequencing and Geno-
typing Core performed sequencing with a read depth of 20–30 million reads per sample for 75
bp with paired-end reads. The raw sequence reads in FASTQ format were aligned to the Rhe-
sus (Macaca mulatta) genome build MMUL1.0 using STAR [19]. Differential expression anal-
yses comparing oral Beta-P and the clinical treatment was performed using DESeq2 [20].
Genes were considered differentially expressed based in their fold-change relative to control
(= or >1.5), p-value (<0.05) and q-value (<0.1).
Functional enrichment and pathway analysis
Lists of differentially expressed genes were used for functional enrichment analysis using the g:
Profiler web server filtered to exclude electronic GO annotations and false discovery rate
adjustment by the Benjamin-Hochberg method [21]. Enrichment p-values are presented as log
p-values with negative values representing terms associated with suppressed genes and positive
values representing terms associated with induced genes.
Statistics
Values are given as means ± SD with 2 group comparisons using T-tests or multiple compari-
sons using ANOVA as appropriate.
Results
Pharmacokinetics
Our measurements in primates were guided by pharmacokinetic and lung maturation mea-
surements that we have made in a fetal sheep model using Beta-P+Beta-Ac and Beta-Ac given
maternal intramuscular, Beta-P given by maternal infusions and oral treatments with Beta-P
and Dex-P [11, 13, 15]. In the fetal sheep, plasma Beta levels in the range of 1 to 4 ng/mL
caused lung maturation if maintained for at least 24 hrs. [13, 22]. A dose of 0.125 mg/kg Beta-
Ac also caused lung maturation in the monkey and a lower dose was not effective [12]. We
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used the effective dose of 0.125 mg/kg of the Beta-Ac component of the clinical combination
drug to determine maternal blood levels that should be effective for lung maturation. Fetal
plasma Beta levels from Beta-Ac were 2.2 ± 0.4 ng/mL at 1hr. with the highest value of
5.9 ± 2.4 ng/mL at 8hr. and with minimal clearance to 24 hr. in non-pregnant monkeys (Fig 1,
Table 2). In pregnant humans, oral Dex-P has a bioavailability of about 75% of intramuscular
Dex-P in two reports [23, 24]. Therefore, we increased the oral doses of Dex-P and Beta-P to
0.15 mg/kg for equivalence with the Beta-Ac results. Oral dosing with 0.15 mg/kg Dex-P or
Beta-P yielded comparable blood levels in nonpregnant monkeys of 17.4 ± 5.9 and 16.8 ± 5.6
ng/mL at 3 hrs., values that were about 4-fold higher than for Beta-Ac. Both drugs had rapid
oral absorption that was similar. The subsequent half-life values of 3.3 hrs. for Dex and 7.4 hrs.
for Beta were quite different with maternal blood levels at 24 hrs. of 2.9±1.4 ng/mL for Beta
and 0.22 to 0.07 ng/mL for Dex. Therefore, for considerations of oral dosing, either drug
achieved higher initial plasma levels more rapidly than Beta-Ac, but the slower clearance of
Beta would favor Beta-P for oral dosing as re-treatment would be needed less frequently to
keep the steroid level above 1 ng/mL. The plasma levels of a low dose of 0.04 mg/kg oral Dex-P
were about 25% of the high dose, indicating proportionate exposures based on dose. This
experiment provided us with information to estimate fetal plasma levels for testing oral mater-
nal treatments in pregnant monkeys.
We then did a minimal sampling protocol of paired maternal blood and ultrasound guided
fetal blood collections at 6 hr, 12 hr, and 24 hr after treatment without complications or loss of
a fetus. We again used maternal intramuscular 0.125 mg/kg Beta-Ac as the known effective
dose and the same 0.15 mg/kg oral Dex-P (Fig 2). Beta levels from Beta-Ac were essentially
Fig 1. Pharmacokinetics of corticosteroids in non-pregnant reproductive age Rhesus macaque given on a linear scale (A) and log scale of concentration (B). The
separate groups of 3 animals were treated with 0.15 mg/kg dexamethasone phosphate orally, 0.04 mg/kg dexamethasone phosphate orally, 0.15 mg/kg betamethasone
phosphate orally, or 0.125 mg/kg betamethasone acetate intramuscular. Blood samples were collected over 24 hr. for analysis of betamethasone or dexamethasone in
plasma and reported as ng/mL.
https://doi.org/10.1371/journal.pone.0222817.g001
Table 2. Pharmacokinetic measurements from non-pregnant Rhesus.
Beta-Ac
0.125 mg/kg IM
Dex-P
0.15 mg/kg PO
Beta-P
0.15 mg/kg PO
Dex-P
0.04 mg/kg PO
Cmax (ng/mL) 6.1 ± 2.2 26.2 ± 14.8 20.3 ± 2.3 6.1 ± 0.7
AUC 24 113 ± 38 134 ± 32 226 ± 23 32 ± 6.8
t1/2 (hrs.) N/A 3.3 2.5 7.4
N/A: The half-life (t1/2) after intramuscular Beta-Ac could not be estimated.
https://doi.org/10.1371/journal.pone.0222817.t002
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constant over 24 hrs. in the maternal plasma at about 2.5 ng/mL, a value lower than the value
of about 5 ng/mL in the non-pregnant animals. Fetal blood levels also were stable over 24 hrs.
at about 1 ng/mL with an average fetal to maternal ratio of 0.42. The oral Dex-P yielded a
higher maternal plasma value of 10.4 ng/mL at 6 hr. but by 24 hr. the value was 0.7±0.4 ng/mL
with a half-life of 4.8 hr. Maternal blood Dex levels were similar to the levels for the nonpreg-
nant monkeys. The t1/2 for Dex in fetal blood was 4.3 hrs. from 6 to 24 hrs. with a maternal
half-life of 4.8 hr. In 3 animals we also had paired maternal and fetal blood sampling at 12 hr.
only following a maternal dose of 0.15 mg/kg Beta-P (Fig 2). The maternal values were compa-
rable to the oral Dex-P levels in the non-pregnant monkey with a fetal to maternal ratio for
Beta of 0.49. Given the slower clearance of Beta from the maternal circulation, estimated fetal
levels at 24 hr. should be about 1.5 ng/mL.
Lung pharmacodynamic effects
We then tested oral Beta-P and oral Dex-P in comparison to saline controls and the positive
control with two intramuscular doses of 0.25 mg/kg Beta-Ac + Beta-P given 24 hrs. apart. We
measured pressure-volume curves 5 days after the initial dose to assess static lung compliance
by the gas volumes in the lung at 40 cm H2O peak pressure (V40), (Fig 3). Based on the low
fetal plasma levels at 24 hr. for oral Beta-P and Dex-P (Fig 2) we tested efficacy with 3 oral
Fig 2. Pharmacokinetics of corticosteroids in maternal and fetal plasma. Groups of 4 pregnant monkeys were treated with maternal intramuscular 0.125 mg/kg
betamethasone-acetate, maternal oral 0.15 mg/kg dexamethasone-phosphate or maternal oral 0.15 mg/kg betamethasone-phosphate (Beta-P). Paired maternal and fetal
blood samples were collected 6, 12 and 24 hr. after the intramuscular betamethasone-acetate and oral dexamethasone-phosphate treatments and only at 12 hr. for the
betamethasone-acetate. Plasma levels are reported as ng/mL. The insert gives the ratios for fetal to maternal drug ratios.
https://doi.org/10.1371/journal.pone.0222817.g002
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doses of 0.15 mg/kg given at 12 hr. intervals. Beta-P given as three 0.15 mg/kg oral doses sepa-
rated by 12 hrs. yielded pressure-volume curves that were significantly different from controls
and were similar to the mean curve for the clinical dosing. The qualitative V40 and deflation
stability values were not significantly different relative to the saline control for the 8 animals
treated with Dex-P. Of note, 2 of the 8 animals had increased lung gas volumes comparable to
the mean value for the clinical treatment with 2 intramuscular doses of 0.25 mg/kg Beta-P
+ Beta-Ac. With low dose 0.04 mg/kg oral Dex-P treatment given as 4 doses at 6 hr. intervals
the mean pressure volume curves demonstrated no effect. We also gave 2 doses of 0.125 mg/kg
of Dex-P separated by 24 hr. to three animals that were used for maternal to fetal drug transfer
measurements. The V40 values were 18 ± 5 ml/kg, which was not different than for the saline
control curves of 16 ± 2 ml/kg at 5 days. Sat-PC in the alveolar washes qualitatively increased
in the 3 steroid treated groups but was not significant for any group because of highly variable
values (Table 3). Surfactant protein D (SP-D) also was measured in the alveolar wash and was
not different across groups. Selected mRNA measurements associated with lung maturation
were measured by PCR, and there were no changes in these mRNA values relative to the con-
trols at 5 days.
Other effects of the treatments
Only the clinical treatment caused suppression of maternal cortisol at 5 days (Table 3). The
fetal weights (Table 1), lung weights and thymus weights (Table 3) were not different across
the 5 day treatment groups. The dam white blood cell values, lymphocyte classes and glucose
values also were not different at 5 days.
RNA-sequencing
In order to identify differential pulmonary and systemic effects of the oral Beta-P treatment
compared to the 2-dose clinical treatment we compared the transcriptome profiles of the
lungs, liver and hippocampus of 4 animals in each group. We previously reported that the clin-
ical drug has a large impact in the lung and hippocampus transcriptome at an early timepoint
of 4h with decreased effects at 5 days [12]. Here we compared the two treatments to each other
to explore differential effects of oral dosing and the intramuscular clinical treatment. Principal
Fig 3. A. Pressure-volume curves and B. maximal lung gas volumes measured at 40 cmH2O pressure for groups of 6 to 8 fetuses 5 days after the maternal
treatments as indicated. The clinical treatment and oral Beta-P group were significantly different from saline controls (p<0.05).
https://doi.org/10.1371/journal.pone.0222817.g003
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component analysis showed similarity between groups with little separation between the sam-
ples in the two groups (Fig 4A). There were no differentially expressed genes in the hippocam-
pus between the two treatments. In the lung, relative to the clinical treatment, oral Beta-P
induced 118 and suppressed 236 genes in the lung. The induced genes in the lung were associ-
ated with biological processes of cellular division while suppressed genes were associated with
developmental processes and differentiation (Fig 4B). In the liver, oral Beta-P induced 145
and suppressed 156 genes relative to the clinical treatment. Induced genes were associated
with myeloid cell differentiation and suppressed genes were associated with developmental
processes, including morphogenesis and angiogenesis (Fig 4C). The top differentially
expressed genes are listed in Fig 5. There were no significant differences in the transcriptome
of the hippocampus between groups.
Discussion
The standard of care for ACS is by repeated maternal intramuscular injections, using several
fluorinated corticosteroid preparations that cross the placenta to the fetus [10, 25]. However,
the pharmacokinetics to establish optimal drug choice, dose and treatment were never evalu-
ated [9]. Other routes of treatment have been reported but have been minimally studied [10].
Fetal intramuscular steroids were considered for human use to selectively target the fetus, but
fetal intramuscular corticosteroids were not as effective as maternal ACS in sheep models [26].
Intravascular ACS using Dex-P also has been reported but will cause very high maternal
Table 3. Measurements at 5 days after treatment.
Control Saline Clinical—0.25 mg/kg Beta-P + Beta-Ac
(0 and 24 hrs.)
Oral Dex-P
0.15 mg/kg
(0, 12, 24 hrs.)
Oral Beta-P
0.15 mg/kg
(0, 12, 24 hrs.)
Fetal weight (g) 320 ± 37 330 ± 46 331 ± 48 300 ± 34
Lung weight / fetal weight (g/kg) 20 ± 10 26 ± 2 24 ± 3 27 ± 4
Thymus weight / fetal weight (g/kg) 3.4 ± 0.8 2.6 ± 0.5 2.7 ± 0.3 2.5 ± 0.7
In Bronchoalveolar Lavage
Sat Phosphatidylcholine (μm/kg) 0.12 ± 0.05 0.68 ± 0.89 0.13 ± 0.13 0.13 ± 0.13
Surfactant Protein-D (ng/mL) 457 ± 216 776 ± 438 733 ± 580 733 ± 580
In maternal blood
CD-4 lymphocytes % total 8.7 ± 3.7 8.4 ± 3.9 6.1 ± 4.0 4.5 ± 8.3
CD-8 lymphocytes % total 7.1 ± 3.4 8.7 ± 3.3 7.6 ± 2.7 4.8 ± 2.7
B cells % total 3.8 ± 2.4 3.9 ± 1.7 3.1 ± 0.8 2.9 ± 1.4
Cortisol (μg/dL) 17.1 ± 0.3 10.8 ± 4.5� 18.6 ± 10 15.9 ± 7.8
In fetal blool
Cortisol (μg/dL) 2.9 ± 0.8 2.0 ± 0.5 3.2 ± 0.8 2.4 ± 0.6
In mRNA fetal lung tissue
SP-A 1 ± 0.35 1.36 ± 0.57 1.35 ± 0.68 1.47 ± 1.10
SP-B 1 ± 0.28 1.31 ± 0.47 0.97 ± 0.29 0.94 ± 0.38
SP-C 1 ± 0.48 1.22 ± 0.54 0.72 ± 0.24 0.65 ± 0.27
SP-D 1 ± 0.33 1.16 ± 0.39 1.01 ± 0.27 0.87 ± 0.34
ABCA3 1 ± 0.17 1.23 ± 0.30 1.06 ± 0.37 1.00 ± 0.43
LAMP3 1 ± 0.27 1.10 ± 0.67 0.72 ± 0.15 0.67 ± 0.33
LPCAT1 1 ± 0.18 1.26 ± 0.36 1.18 ± 0.41 0.92 ± 0.41
SCNN1G 1 ± 0.28 1.15 ± 0.30 1.15 ± 0.32 0.94 ± 0.32
�p<0.05 compared to control
https://doi.org/10.1371/journal.pone.0222817.t003
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plasma corticosteroid levels. There are no experimental reports of oral ACS in animals, and
the clinical experience with oral ACS is limited to one trial and case reports. Egerman and col-
leagues reported in 1997 the pharmacokinetics of 6 mg intramuscular Dex-P and 8 mg PO
Dex-P in third trimester pregnant women [27]. Peak plasma levels for maternal oral Dex were
about 65% of intramuscular levels with peak concentrations at 30 min. for intramuscular and 2
hr. for PO treatments. Plasma half-life values and bioactivity were similar. They then reported
a clinical trial in 1998 for women at risk for preterm delivery to receive 4 doses of 6 mg Beta-P
intramuscular or 4 doses of 8 mg Beta-P PO, repeated at 12 hr. intervals [23]. This study was
stopped at 39% enrollment for more neonatal sepsis and intraventricular hemorrhage in the
oral treatment group. There was no explanation for the increase in adverse outcomes with the
oral treatment, but the adverse outcomes were lower than expected in the intramuscular
treated patients. This trial is a cautionary note indicating that careful monitoring is essential
for future trials with oral ACS.
For low resource environments where drug stability, safety and cost are of paramount con-
cern, oral ACS may have many advantages. Beta-P and Dex-P are available as pills or solutions
worldwide and are used as oral preparations for multiple indications [14]. This exploratory
study was designed as an initial proof of principle of oral ACS using a primate model. We eval-
uated the pharmacokinetics of oral Beta-P and Dex-P as they are the two fluorinated cortico-
steroid drugs routinely used for ACS. Our comparison was to the slowly solubilized
intramuscular Beta-Ac to calibrate oral dosing against an effective treatment with low fetal
exposures that we had characterized in sheep and primate models [11, 12, 15]. In humans, oral
Dex-P is rapidly absorbed with a time to peak concentration that is similar or slightly longer
Fig 4. A. Principal component analysis of transcriptomic profiles of fetuses treated with the clinical treatment or oral Beta-P (n = 4 animals/group). B. Biological
processes associated with differentially regulated genes in the lung. C. Biological processes associated with differentially regulated genes in the liver.
https://doi.org/10.1371/journal.pone.0222817.g004
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than for intramuscular Dex-P and with a clearance half-life of about 4 hrs. in adult men [28].
Peak blood levels of Dex after oral Dex-P are about 70% of the levels following intramuscular
Dex-P with clearance half-life values of about 4 hrs. with similar bioavailability for the oral
treatment ranging from 70–100% [24, 27]. There is a lack of information comparing oral and
intramuscular Beta-P in humans. There also is no information for efficacy of lower doses of
these drugs for ACS.
In the non-pregnant female monkey, oral absorption of Dex and Beta were equivalent, but
the clearance rate was substantially slower for Beta than for Dex. In the pregnant animals our
limited measurements demonstrated stable and low maternal plasma levels from 0.125 mg/kg
Beta-Ac of about 2 ng/mL Beta and fetal plasma levels of about 1 ng/mL for the 3 measure-
ments at 6, 12 and 24 hrs. The fetal to maternal Beta ratio was 0.4 in cord blood, which was
similar to values reported for humans [24, 29]. The oral dose of 0.15 mg/kg Dex-P demon-
strated a maternal half-life of 4.8 hr. and a fetal half-life of 4.3 hr. from 6 to 24 hrs. resulting in
a fetal Dex level of< 1 ng/ml by 24 hrs.
For evaluation of treatment effects, we used the doses for which we had the pharmacoki-
netic measurements in comparison to the much higher clinical treatment with 0.25 mg/kg
Beta-P + Beta-Ac given as 2 doses separated by 24 hrs. We assume the clinical treatment causes
a maximal ACS response [8]. The lung gas volume responses were measured at 5 days after
treatment initiation to be within the interval of 24 hr. to 7 days for clinical benefit [4, 30]. The
only physiological measurement available to us with the monkey was the pressure-volume
curve. This measurement has reliably predicted dynamic compliance and gas exchange matu-
rational signals in sheep models, including for oral treatment [15]. Statistically, the 0.15 mg/kg
oral Beta-P given as 3 doses at 12 hr. intervals was different from the controls and not different
from the clinical treatment. The V40 values were more scattered with the 3 dose 0.15 mg/kg
Dex-P treatment with 2 of 8 with high V40 values but 6 values were not different from control.
The 4 doses of 0.04 mg/kg oral Dex group were clearly not effective. Based on our demonstra-
tion that the sustained fetal Beta levels achieved with Beta-Ac are sufficient for lung maturation
in sheep and monkeys [11, 12], and the oral fetal Beta level measured at 12 hr. in 2 animals of
2.35 ± 0.05, lung maturation should have occurred (Fig 2). The fetal Dex level of 2.2 ± 0.6 mea-
sured for the oral Dex dose of 0.15 mg/kg also should have been effective, but variability
between animals and the possibility that Dex and Beta are not equivalent by potency may
explain the lack of effect. In humans, the 2-dose ACS treatment decreased respiratory distress
syndrome by only 40%, and ACS treatments in animal models consistently have variable
responses with animals that do not have lung maturation responses [1, 11]. In this study, 2 of
the 6 animals given the high 2 dose clinical treatment were in the range of the control animals
(Fig 3). Variable responses and the limitation of animal numbers when using primates makes
these experiments of low sensitivity.
In a previous study with this same model with primates, single doses of intramuscular 0.25
mg/kg Beta-P+Beta-Ac and 0.125 mg/kg Beta-Ac increased the amount of Sat PC in the alveo-
lar lavage at 5 days as an indicator of increased surfactant by ACS [12]. In this experiment, two
dose of 0.25 mg/kg Beta-P+Beta-Ac or oral dosing with Beta-P or Dex-P did not significantly
increase SAT-PC. The estimates of surfactant pool sizes are remarkably low—0.25 mg/kg for
controls and 0.66 mg/kg for the two dose 0.25mg/kg Beta-P+Beta-Ac. Similarly, surfactant
protein D did not increase, and we did not have assays for the other surfactant proteins. The
panel of mRNAs as indicators of maturation also were not increased at 5 days, a result we
Fig 5. Top differentially expressed genes by RNA-sequencing in the lung and liver of animals treated with Oral
Beta-P compared to the clinical treatment. Values are expressed as log fold change (logFC).
https://doi.org/10.1371/journal.pone.0222817.g005
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anticipated. In sheep models, increases in mRNA occur quickly after fetal exposure to ACS or
inflammation, but the mRNA values return to control values within a few days [31]. The same
phenomenon has been described for explants from early gestation human lung [32].
We showed in the primate model that eliminating unnecessary peak fetal exposure to ante-
natal corticosteroids decreases potentially toxic effects identified in the fetal hippocampus by
transcriptome analysis [12]. Despite the higher dose that was administered orally, the differ-
ences in the transcriptome of the liver and lung after oral treatment with Beta-P compared to
the clinical treatment were small and do not indicate the potential for increased toxicity. In the
lung Beta-Ac had increased expression of genes associated with cellular proliferation. Suppres-
sion of cellular proliferation is a known effect of corticosteroids that we had previously
observed with a single dose of the clinical drug and here we observe with 2 doses of the clinical
drug relative to the oral Beta-Ac. The suppression of genes associated with development likely
reflect effects of corticosteroids on differentiation and maturation pathways but are of unclear
significance as the genes affected are not important mediators of fetal lung maturation and the
functional maturation measured by lung compliance was similar between the two treatments.
More importantly, there were no differences in the hippocampus transcriptome showing that
the oral dose does not expose the fetus to additional potential risks to neurodevelopment com-
pared to the clinical treatment.
The experiments have limitations inherent to studies in primates. Our assessments of lung
responses in small experimental group sizes compromised the sensitivity of the studies. In con-
trast to similar studies in sheep models, we did not attempt to ventilate the preterm monkeys
after delivery to evaluate dynamic lung mechanics and gas exchange [12]. The pregnant mon-
keys had lower plasma corticosteroid levels than did the non-pregnant monkeys, which needs
to be further evaluated in the human. The clearance kinetics for Beta and Dex were quite dif-
ferent. Any future clinical studies of oral dosing of ACS need to consider the pharmacokinetics
of the drug chosen for evaluation.
In conclusion, oral ACS treatments are feasible. Dosing can be adjusted based on pharma-
cokinetics to achieve fetal exposures that avoid high and unnecessary fetal plasma corticoste-
roid levels, as demonstrated for intramuscular treatments [33]. Reliable oral dosing may
depend on variable such as recent food consumption, maternal weight which will need to be
explored clinically. This report together with our other recent studies in sheep and monkey
models establish the rational for developing knowledge based approaches to new ANS treat-
ment strategies [12, 15].
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